Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Epivir (3TC, Lamivudine)

The Basics | News | Research

See also: Drug Interactions | Medication Side Effects

Show Archived (Historical) Articles

Brand Name:	Epivir
Generic Name:	Lamivudine, 3TC
Adult Single Dose:	One 150-mg tablet (twice a day) OR one 300-mg tablet (once a day)
Food & Liquid Restrictions:	None
Drug Class:	NRTI

The Basics

An Overview of Epivir (3TC, Lamivudine) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Epivir (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Lamivudine (Epivir) (November 20, 2008)
To read PDF, click here
From AIDS InfoNet
Epivir (Lamivudine, 3TC) (September 28, 2008)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Patient Information About Epivir (3TC, Lamivudine) (PDF) (February 2008)
From GlaxoSmithKline
3TC (Epivir, Lamivudine) (October 26, 2006)
From AIDS Treatment Data Network
Epivir (Lamivudine) (September 6, 2006)
To read PDF, click here
From The Center for AIDS

News

Epivir Tablets for Pediatric Dosing (February 7, 2008)
From U.S. Food and Drug Administration
Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
WHO Approves New Generic Lamivudine, Fluconazole Pills (July 14, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
WHO Removes Cipla's Lamivudine, Zidovudine Generics From Approved Drug List (June 16, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis

Research

Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.